Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $217,000 | 10 | 100.0% |
| Food and Beverage | $73.27 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $217,000 | 10 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $28.61 | 1 | $0 (2023) |
| Lilly USA, LLC | $19.87 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 1 | $0 (2018) |
| Allergan Inc. | $11.66 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $48.48 | 2 | Janssen Pharmaceuticals, Inc ($28.61) |
| 2021 | $80,600 | 4 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($80,600) |
| 2020 | $136,400 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($136,400) |
| 2018 | $13.13 | 1 | E.R. Squibb & Sons, L.L.C. ($13.13) |
| 2017 | $11.66 | 1 | Allergan Inc. ($11.66) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $28.61 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/24/2023 | Lilly USA, LLC | EMGALITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Neuroscience | ||||||
| 03/16/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $15,500.00 | General |
| 01/07/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $24,800.00 | General |
| 01/07/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $24,800.00 | General |
| 01/07/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $15,500.00 | General |
| 11/16/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $31,000.00 | General |
| 08/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $27,125.00 | General |
| 08/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $24,800.00 | General |
| 07/07/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $26,350.00 | General |
| 07/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $15,500.00 | General |
| 05/08/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $11,625.00 | General |
| 05/22/2018 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.13 | General |
| Category: Cardiovascular | ||||||
| 08/14/2017 | Allergan Inc. | BYSTOLIC (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: CARDIOVASCULAR | ||||||
About Dr. Bruce Leslie, M.D
Dr. Bruce Leslie, M.D is a Nephrology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689696452.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Leslie, M.D has received a total of $217,073 in payments from pharmaceutical and medical device companies, with $48.48 received in 2023. These payments were reported across 14 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($217,000).
Practice Information
- Specialty Nephrology
- Location Washington, DC
- Active Since 07/24/2006
- Last Updated 05/28/2022
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689696452
Products in Payments
- XARELTO (Drug) $28.61
- EMGALITY (Drug) $19.87
- ELIQUIS (Drug) $13.13
- BYSTOLIC (Drug) $11.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Washington
Dr. Lakhmir Chawla, Md, MD
Nephrology — Payments: $467,296
Robert Rubin
Nephrology — Payments: $254,868
Dr. Janani Rangaswami, Md, MD
Nephrology — Payments: $110,913
Mr. Christopher Wilcox, M.d, M.D
Nephrology — Payments: $84,704
Dominic Raj, Md, MD
Nephrology — Payments: $23,952
Michael Lipkowitz, Md, MD
Nephrology — Payments: $19,429